Tokyo and Akita, Japan, September 30, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) and UMN Pharma Inc. (“UMN Pharma”; headquarters: Akita, President & CEO: Shu-Ichi Kanazashi) announced today that the both companies entered into the definitive agreement for UMN-0501 and UMN-0502 (the “Licensed Programs”), which are cell culture based influenza vaccine programs developed by UMN Pharma, on September 21, 2010. Under the agreement, the both companies will co-develop the Licensed Programs and Astellas will exclusively commercialize them in Japan. The execution of a memorandum of understandings as of August 16, 2010 was already announced on August 17, 2010.


【Outline of definitive agreement】
・Astellas is granted co-development and exclusive commercialization rights for the Licensed Programs in Japan
UMN-0501 is a cell culture based H5N1 avian influenza vaccine.
Currently, it is under preparation for Phase III clinical trial in Japan.
UMN-0502 is a cell culture based seasonal influenza vaccine.
Currently, it is under preparation for Phase I/II clinical trial in Japan.
・Astellas will lead the further development and bear all the costs.
・UMN Pharma is responsible for manufacturing, will supply the final commercial products to Astellas, and Astellas will be selling the commercial products.

Contact the Media Relations team
Communications & Investor Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)